Effects of Gliadin on Autoimmune Responses of Central Nervous System of C57BL/6 Mice

Parisa Esmaeili1,2, Elham Rostami3, Arefeh Akbarijavar4, Alireza Akbari Meyestani5, Hamed Bashiri6, Mohammad Ali Rezaee7,8, and Shohreh Fakhari1,9

1 Department of Immunology and Hematology, Faculty of Medicine, Kurdistan University of Medical Sciences, Sanandaj, Iran
2 Department of Epidemiology, Pasteur Institute of Iran, Tehran, Iran
3 Department of Biology, School of Science, Shahid Chamran University of Ahvaz, Ahvaz, Iran
4 Graduated from Faculty of Veterinary Medicine, Shahid Bahonar University of Kerman, Kerman, Iran
5 National Institute of Genetic Engineering and Biotechnology (NIGEB), Tehran, Iran
6 Department of Laboratory Sciences, Faculty of Paramedical, Kurdistan University of Medical Sciences, Sanandaj, Iran
7 Zoonoses Research Center, Research Institute for Health Development, Kurdistan University of Medical Sciences, Sanandaj, Iran
8 Department of Medical Laboratory Sciences, Faculty of Paramedical, Kurdistan University of Medical Sciences, Sanandaj, Iran
9 Cancer and Immunology Research Center, Research Institute for Health Development, Kurdistan University of Medical Sciences, Sanandaj, Iran

Received: 1 September 2019; Received in revised form: 17 September 2020; Accepted: 27 September 2020

ABSTRACT

Gluten sensitivity contributes to various degrees of neurological manifestations and neurodegenerative immunological changes. We investigated the experimental features of anti-gliadin immune responses in the central nervous system (CNS) of mice.

Female C57BL6 mice were divided into three groups. Mice immunized with complete Freund's adjuvant (CFA) or gliadin emulsified in CFA, and the control group received phosphate-buffered saline (PBS). Immunohistochemistry, hematoxylin eosin, and Luxol fast blue staining were performed on the sections. The serum levels of interleukin (IL)-17 and interferon-gamma (IFN-γ) were measured using enzyme-linked immunosorbent assay (ELISA). Reverse transcriptase-polymerase chain reaction (RT-PCR) was used to assess the mRNA levels of chemokine (C-X-C motif) ligand-2 (CXCL-2), C-C motif chemokine ligand-2 (CCL-2), and CXCL-10.

In gliadin+CFA immunized mice, the microscopic lesions included perivascular edema, focal-microgliosis, and acute neuronal necrosis in the cortex, subcortical, Purkinje cell layer, and ventral horn of the spinal cord. While extravasation of anti-IgG antibodies and selective targeting of Purkinje cells were observed in gliadin+CFA immunized mice. A significant increase in serum IL-17 and IFN-γ levels (p<0.05), as well as expression of CXCL-2, CCL-2, and CXCL-10 in mice immunized with gliadin+CFA, were monitored versus controls.

Our findings indicated that the immune responses directed against gliadin peptides might...
Gliadin on Autoimmune Responses of Central Nervous System

contribute to blood-brain barrier breakdown, extravasation of serum anti-IgG, gliosis, and acute neuronal necrosis in the cortex and cerebellar Purkinje cells. Anti-IgG antibodies may cause extravasation of blood-born anti-gliadin antibodies and selective targeting of Purkinje cells observed in mice immunized with peptide tryptic (pt)-gliadin in CFA.

**Keywords:** Central nervous system; Gliadin; Immunity; Neurological disorder

**INTRODUCTION**

Tolerance toward nutritional antigens is considered a complicated process related to various human disease states. Accordingly, celiac disease (CD) as enteric intolerance to a dietary antigen is accompanied by enteropathy following gluten ingestion. Glutens area group of proteins that originate in wheat, barley, and rye. Gluten contains diverse proteins (comprising gliadins and glutenins) and immunogenic amino acid sequences that are pathogenic in the context of CD. Previous studies have mainly confirmed the nervous system (NS) as a complication of pre-diagnosed CD. Other reports have indicated that a wide range of neurological disorders might present gluten intolerance's extraintestinal manifestation. Besides, a high incidence of other autoimmune diseases has been recognized among CD individuals. Neurological complications, including demyelinating disorders such as multiple sclerosis (MS), have also been reported to contribute to the CD. In this regard, T helper 1 (TH1) cells, with their main cytokine, interferon-gamma (IFN-γ), and TH17 cells with interleukin-17 (IL-17) have vital roles in experimental autoimmune encephalomyelitis (EAE) pathogenesis, which is an experimental model for the human inflammatory demyelinating disorder, MS. Moreover, chemokines, and their receptors play essential roles in leukocyte trafficking and are engaged in immune responses provoked in the central nervous system (CNS). Indeed, their roles are associated with the large numbers of neuro-pathologies comprising MS.

IL-17, as an inflammation inducer, has regulatory effects on chemokine (C-X-C motif) ligand-2 (CXCL-2) production. Since T-cell accumulation in the CNS has a crucial role in MS pathogenesis, and large numbers of T cells within the cerebrospinal fluid (CSF) section express the CXCR3, the role of prolonged CXCR3 T cells accumulation in the MS lesion development was proposed. It has been shown that CXCR3 ligand expression, IFN-γ -inducible protein/CXCL-10, has increased in MS, contributing to demyelination. CXCL-10 provokes T cells accumulation in MS pathogenesis. Another chemokine that recruits immune cells in the CNS during EAE is C-C motif chemokine ligand-2 (CCL2), which has been proposed as a new target for medical intervention in neuroinflammatory disorders.

Gluten sensitivity contributes to various degrees of neurological manifestations associated with an immunological attack on the CNS and neurodegenerative changes. Studying molecular mechanisms of a potential linkage between neurological manifestations and gluten sensitivity could significantly affect sufferers. Thus, the present experimental study was conducted to investigate the histopathological and biochemical features of anti-gliadin immune responses in mice CNS.

**MATERIALS AND METHODS**

**Preparation of Peptic-tryptic Digests of Gliadin**

The peptic-tryptic (pt) digest of gliadin was prepared according to the previously published protocol. Briefly, 100 mg of gliadin (Sigma-Aldrich, Canada) was suspended in 2 mL HCl (0.1 N, pH: 1.8) (Merck, Germany) and then incubated with 3 mg pepsin (Bio Basic, Canada Inc; specific activity: 3 000-3500 U/mg) for 4 hours at 37°C in shaking incubator. After adjusting pH to 7.8, further, incubation was performed with 3 mg trypsin (Sigma Chemical, St. Louis, MO, USA; specific activity: 3000-3500 U/mg) for 4 hours at 37°C in shaking incubator. After adjusting pH to 7.8, further, incubation was performed for 4 hours with 3 mg trypsin (Sigma Chemical, St. Louis, MO, USA; specific activity: 1000-1500 U/mg). The activity of digestive enzymes was stopped by incubating in boiling water for 10 minutes.

**Animals**

Sixty eight weeks-old female C57BL/6 mice were selected. All mice were kept under controlled conditions with ad libitum access to food and water. This experimental study was approved at Kurdistan University of Medical Sciences (grant number: 14/30408/414) (Ethic code: IR. MUK. REC.1393. 414).
Experimental Protocol

The mice were randomly divided into three groups (10 mice in each group). In group 1, the mice received subcutaneously (SC) phosphate-buffered saline (PBS) (400 µL). In group 2, the mice have immunized SC with complete Freund’s adjuvant (CFA) (400 µL), and in group 3, the mice have immunized SC with ptgliadin (300 µg) emulsified in CFA (400 µL). Boosters containing the same amount of antigen were injected on days 7 and 14.

Histopathological Analysis

After 28 days, the mice were euthanized, and their brain and spinal cord tissues were removed. All tissue samples were initially fixed in buffered formalin (not exceeding 10% formaldehyde) before embedding in paraffin. After preparing tissues, each group’s sections were stained with hematoxylin-eosin (H&E) and Luxolfast blue (LFB). The histopathological changes were considered the main neurohistopathological manifestations.

Immunohistochemistry

Briefly, 5 µm sections prepared from the tissues were deparaffinized in xylene and then were rehydrated in graded ethanol. After rinsing in distilled water, antigen retrieval was performed by heat treatment at 98°C in citrate buffer (pH: 6.0). Neutralization of endogenous peroxidases was carried out by incubating the sections in 3% H₂O₂ in PBS. Subsequently, the sections were detected for extravasated IgG using incubation with a sheep anti-mouse IgG antibody (Avicenna Research Institute, Iran) at a 1:100 dilution ratio for one hour. After rinsing with 0.01M PBS, samples were incubated with peroxidase-conjugated rabbit anti-sheep antibody (Avicenna Research Institute, Iran) at a 1:100 dilution ratio as the secondary antibody. The sections were then rinsed again and incubated in 100 µL dianinobenzidine (DAB) (Bio Basic Inc, Canada) for 10 minutes. After rinsing with 0.01 M PBS four times, the sections were air-dried, dehydrated in graded ethanol, and cleared in xylene. The sections were examined with Olympus BX-41 microscope.

Serum Levels of IFN-γ and IL-17

Twenty-eight days following injection, retro-orbital blood was drawn from the eyes of the mice. The blood sample was immediately centrifuged at 4°C for 5 min at 4000 rpm, and serum samples were stored at -20°C until enzyme-linked immunosorbent assay (ELISA) tests were performed. During the experiment, the sera were melted, and IL-17 and INF-γ were measured by the ELISA method utilizing commercial kits (eBioscience, USA) according to the kit instructions (sensitivity of IFN-gamma 15 pg/mL, the sensitivity of IL-17; 4 pg/mL).

Reverse Transcription-polymerase Chain Reaction Assay (RT-PCR)

RNA was extracted from frozen brain and spleen tissue; using a total RNA extraction kit (ParsTous, Iran), based on the manufacturer's instructions. Then, the equal amounts of RNA were reverse-transcribed into cDNA with the cDNA synthesis kit (ParsTous, Iran), containing random hexamer.

An RT-PCR was carried out to investigate the expression levels of CXCL-10, CCL-2, and CXCL-2 in the spinal cord and brain samples. According to the manufacturer's protocol, RT-PCR examinations were performed with PCR master mix (ParsTous, Iran). The primer set is presented in Table 1. Thermocycling of each reaction was performed with each primer at a concentration of 1 µL. The following protocols were

| Gene   | Sequence                  | Product Size (bp) |
|--------|---------------------------|-------------------|
| β-actin| F:5-CTTGGGTATGGAATCTCTGT-3| 97                |
|        | R:5-ACTGTGGCATAGAGGTC-3   |                   |
| CCL-2  | F:5-TCAGCCAGATGCAGTTAACG-3| 117               |
|        | R:5-TCTTTGGGACACCTGCTGC-3|                   |
| CXCL-2 | F:5-TCATAGCCACTCTCAAGGG-3| 151               |
|        | R:5-TGGTTCTTTCCGTTAGGG-3  |                   |
| CXCL-10| F:5-ATCATCCTGCGAGCCTATC   | 202               |
|        | R:5-GGTAAAGGGGAGTATGGAG-3 |                   |
used: denaturation program (94°C for 10 min), followed by the annealing at 56°C (β-actin) and 66°C (CCL-2), 58°C (CXCL-2) and 60°C (CXCL-10) for the 30 s and amplification at 72°C for 45s. The PCR products were analyzed by 2% agarose gel electrophoresis with ethidium bromide staining. A β-actin expression normalized the difference in the initial amount of total RNA among the samples.

**Statistical Analysis**

Statistical analyses were carried out by Graph Pad Prism software, data are shown as means ± SEM, and statistical analyzes were performed using statistical software R version three. One-way variance analysis was used to compare chemokine gene expression and cytokine concentration changes between different groups. Tukey test was also used for post hoc comparisons. Fisher’s exact test was used to correct the histopathological data. The significance level was considered *p*<0.05.

**RESULTS**

To evaluate the histopathological changes in the brain and spinal cord tissues and IgG infiltration into the brain parenchyma, hematoxylin-eosin, Luxol fast blue, and immunohistochemical methods were carried out. Also, serum levels of IL-17, IFN-γ, and mRNA expression of CXCL-10, CCL-2, and CXCL-2 were measured by ELISA and RT-PCR methods.

**Immunohistochemical and Histopathological Results**

Immunohistochemical analysis revealed a significant difference in anti-IgG antibody infiltration rate into the perivascular brain parenchyma. Acute neuronal necrosis was monitored in the cortex subcortical, cerebellum, Purkinje cell layer, and spinal gray matter in the gliadin+CFA immunized group versus control groups. Likewise, there were significant differences in perivascular edema and glial cell proliferation in the gliadin+CFA treated group compared to CFA and PBS control groups (Figures 1 and 2). Results of hematoxylin-eosin staining demonstrated that there was acute neuronal necrosis associated with mild Purkinje cell injury in cerebellar tissues of gliadin+CFA treated mice. Moreover, neuronal necrosis, pre-vascular edema, microgliosis, and cavitation underlying the brain cortex’s injury sites were observed (Figures 1 to 2).

![Figure 1. Hematoxylin-eosin staining of the brain and spinal cord sections.](image-url)
Figure 2. (i) Immunohistochemistry staining of the cerebellar cortex sections. (ii) Hematoxylin-eosin staining of brain sections. Photomicrographs of the cerebellar cortex tissue sections of gliadin+complete Freund's adjuvant (CFA) treated mice (A, B, and C). Extravasation of antibodies along with Purkinje cells (A) and cerebral cortex (B) Brown spots indicate extravasation of anti-IgG Antibodies. Arrows show selective targeting of the Purkinje cell layer by anti-IgG antibodies. Targeting Purkinje cells by anti-antibodies demonstrates the possible cross-reaction between epitopes of gliadin and Purkinje cells. (C) Microscopic lesions included the photomicrograph of focal microgliosis in mice treated with pt-gliadin emulsified in CFA. (D, E, and F) Photomicrographs of the cerebellar cortex in a mouse treated with CFA. (G, H and I) Photomicrographs of the cerebellar cortex in a mouse treated with phosphate-buffered saline (PBS). The mice treated with CFA and PBS, respectively, do not show the extravasation of anti-IgG and its reaction to cells and none of the experimental groups showed microscopic microgliosis. (400X magnification)

Immunological Results

The pattern and serum levels of IFN-γ and IL-17 cytokines secreted by TH1 and TH17 lymphocytes were measured to evaluate gliadin peptides administration effects. As displayed in Table 2 and Figure 3, in gliadin treated mice, serum levels of IL-17 and IFN-γ levels (520±202 and 242±166.5 pg/mL, respectively) were remarkably enhanced compared to the control group CFA (437.5±110 and 292.5±116 pg/mL, respectively) and PBS treated control group (70±42.70 and 87.5±30) (p<0.05).

There were significant differences in serum levels of IL-17 and IFN-γ cytokines in the gliadin peptide treated mice compared to the CFA and PBS groups (p<0.05).

Table 2. Statistical analysis of interleukin (IL)-17 and interferon-gamma(IFN-γ) cytokines

|          | Sum of sequences | Df | Mean square | F    | p     |
|----------|------------------|----|-------------|------|-------|
| **IL-17** |                  |    |             |      |       |
| Between Groups | 81424.150       | 3  | 27141.383   | 87.292 | 0.000 |
| Within Groups   | 4974.800        | 16 | 310.925     |       |       |
| Total            | 86398.950       | 19 |             |       |       |
| **IFN-γ**       |                  |    |             |      |       |
| Between Groups   | 74653.750       | 3  | 24884.583   | 70.972 | 0.000 |
| Within Groups    | 5610.0000       | 16 | 350.625     |       |       |
| Total            | 80263.750       | 19 |             |       |       |

Df; degrees of freedom, F; frequency
Gliadin on Autoimmune Responses of Central Nervous System

Figure 3. The serum level of interleukin (IL-17) and interferon-gamma (IFN-γ) in three experimental groups: Data analysis showed an increase in serum levels of IL-17 (A) and IFN-γ (B) cytokines in the gliadin+complete Freund's adjuvant (CFA) versus phosphate-buffered saline (PBS) and CFA recipient groups (p<0.05). One-way variance analysis was used to compare cytokine concentration changes between different groups. Statistical analyses were carried out by Graph Pad Prism software version six, data are shown as means ± SEM, and statistical analyzes were performed using statistical software R version 3.

Gene Expression Results

RT-PCR assessed the mRNA expression levels of CCL-2, CXCL-2, and CXCL-10 chemokines engaged in inflammatory processes, neuronal degeneration, and immune cells infiltration into the CNS. According to the results of RT-PCR analysis, there was a significant increase in the gene expression levels of CCL-2 and CXCL-10 chemokines in the gliadin+CFA treated group compared to CFA and PBS treated mice (p<0.05) (Figure 4). Besides, there was a meaningful increase in CXCL-2 chemokine expression levels in the gliadin+CFA recipient group versus CFA and PBS control groups (p<0.001) (Figure 4, Table 3).

Table 3. Statistical analysis of mRNA expression of C-C motif chemokine ligand-2 (CCL-2), chemokine (C-X-C motif) ligand-2 (CXCL-2), and chemokine (C-X-C motif) ligand-10 (CXCL-10) chemokines

|          | Sum of sequences | Df  | Mean square | F       | p    |
|----------|------------------|-----|-------------|---------|------|
| CXCL-10  | Between Groups   | 0.427 | 2 | 0.214 | 15.401 | 0.001 |
|          | Within Group d   | 0.125 | 9 | 0.014 |       |      |
|          | Total            | 0.552 | 11 |       |       |      |
| CXCL-2   | Between Groups   | 0.233 | 2 | 0.117 | 35.463 | 0.000 |
|          | Within Group d   | 0.030 | 9 | 0.003 |       |      |
|          | Total            | 0.263 | 11 |       |       |      |
| CCL-2    | Between Groups   | 0.656 | 2 | 0.328 | 358.064 | 0.000 |
|          | Within Group d   | 0.008 | 9 | 0.001 |       |      |
|          | Total            | 0.665 | 11 |       |       |      |

Df; degrees of freedom, F; frequency
Figure 4. The mRNA expression patterns of chemokine (C-X-C motif) ligand-10 (CXCL10), chemokine (C-X-C motif) ligand-10 (CXCL2), and C-C motif chemokine ligand-2 (CCL2) chemokines in experimental groups. There were significant differences in CXCL10 (A), CXCL2 (B), and CCL2 (C) gene expression in the gliadin+complete Freund's adjuvant (CFA) recipient group compared to CFA and phosphate-buffered saline (PBS) treated groups (p<0.05). One-way variance analysis was used to compare chemokine gene expression concentration changes between different groups. Statistical analyses were carried out by Graph Pad Prism software version six, data are shown as means ± SEM, and statistical analyses were performed using statistical software R version 3.

DISCUSSION

The present study indicates that histopathological changes in the brain, increased IFN-γ and IL-17 serum levels, and the upregulation of inflammatory chemokines of CXCL2, CCL2, and CXCL10 might initiate inflammatory processes and leukocyte trafficking and could be considered as related immune-mediated responses against gliadin.

Celiac disease (CD) is a gluten-related autoimmune disorder triggered by poorly ingestion of gluten proteins, especially those derived from gliadins in genetically susceptible individuals. Furthermore, there is increasing evidence that gluten is also associated with the development of numerous extraintestinal autoimmune complications, such as MS. In 2017, an epidemiological study showed that the prevalence of MS in CD patients was 0.1%. Neurological symptoms of CD have been documented in neuroimaging scans, include seizures, cerebellar ataxia, myelopathy, dementia, and progressive leukoencephalopathy. A possible association between CNS related diseases and CD has been suggested through cross-reacted with neural proteins, production of cytokines, increased blood-brain barrier permeability, and the activation of autoreactive T cells. In the present study, we aimed to examine the immune responses in neural tissues after immunization with gliadin and CFA. Based on our obtained results, perivascular edema was the histopathological manifestation in CFA treated mice; nevertheless, in mice immunized with gliadin+CFA, the microscopic lesions were included the perivascular edema, focal microgliosis, acute neuronal necrosis in the cortex, subcortical, cerebellum, Purkinje cell layer, and ventral horn of the spinal cord. Moreover, extravasation of anti-IgG antibodies and Purkinje cells were observed in mice immunized with gliadin in CFA. In this regard, it has been reported that the CNS may be a proposed site of gluten-mediated pathogenesis involving cross-reacting antibodies and further immune-mediated factors.

In the previous studies, the cross-reaction between α-gliadin and various neural antigens has been confirmed. Obviously, gliadin fragment can activate the innate immune system and affects the in situ T-cell recognitions of dominant gliadin epitopes. Moreover, circulating IgG may interact with the brain parenchyma structures by crossing the blood-brain barrier once its penetrability is altered. This phenomenon suggests a probable pathogenic brain disease mechanism mediated by immune responses. Similarly, the previous study displayed that IgG uptake in the rat neurons was related to eosinophilia and degenerative ultrastructural alteration. It could be indicated that IgG leakage is associated with neuronal impairment and might be a pathogenic mechanism in epileptogenesis. Following our results, previous data exhibit that histopathological changes of the CNS in gluten-sensitive cases comprise inflammation in the dorsal root ganglia, degeneration of the posterior columns of the spinal cord, and focal inflammatory cell infiltration in the epineurium and around a small endoneurial blood vessel. In a
similar study, to investigate cross-reactivity between α-gluten antibody and various tissue antigens, Vojdani et al measured the antibody binding to the body antigens, and the most meaningful binding had appeared with neural antigens.27 The previous investigations indicate that anti-gluten antibody in the autoimmune cerebellar ataxia case is related to the loss of Purkinje cells.37,38 Therefore, it is suggested that the neurological alterations during CD are associated with inflammation and cross-reaction of immune responses against gluten peptide. Indeed, gluten may induce immune responses, which are related to autoimmunity.9,38, 39

Our results showed the elevated levels of IFN-γ and IL-17 and upregulation of inflammatory chemokines CXCL-2, CCL-2, and CXCL-10 in further analysis for evaluating the possible mechanism of neurological complications after gluten immunization, which played essential roles in leukocyte trafficking. These data could be considered as possible immune-mediated responses against gluten.

TH1 and TH17 produce IFN-γ and IL-17, respectively, by crossing the blood-brain barrier and encounter CNS antigen-presenting cells. Indeed, they secrete inflammatory mediators, which disrupt the myelin and axons. Likewise, they activate the inhabitant microglia and produce factors that persuade the inflammatory process.14 It could be proposed that IFN-γ had a notable role in increasing the epithelial permeability during inflammation40 since T-cell mediated permeability-increasing activity is impeded by blocking antibodies against INF-γ and effects are reversed by recombinant INF-γ. So, it could be indicated that TH17, through the intermediary role of IL-17A, interrupts the blood-brain barrier and this effect is promoted by oxidative stress induction, which consequently led to down-regulation of the tight junction molecule occluding.41 In agreement with our data, Tanuma et al proposed that monocyte chemotactic protein-2 (MCP-1)/CCL2 and interferon gamma-induced protein-10 (IP-10)/CXCL-10, secreted by astrocytes, might stimulate astrocyte activities and lead to reactive gliosis after migration and activation of microglia/macrophages that are the main effectors in the lesional expansion.42 According to the present knowledge, there are no further similar studies that evaluate the examined chemokine systems after gluten immunization. Although there was no evidence of CNS demyelination in the three examined groups in this study, further studies should be conducted to evaluate the possible relationships between immunization with gluten and demyelinating disorders of the CNS. Due to the lack of time and funding, we were not able to identify anti-gluten antibodies; therefore, a more detailed study is required. Evaluation of the neurotoxicity effect of gluten peptide in transgenic animals (transgenic mice with celiac-related alleles and multiple sclerosis) is an attractive target, and tracing of gluten peptides to track its pathway to the central nervous system in laboratory animals to be placed.

Our findings demonstrate that the immune responses against gluten peptides may contribute to blood-brain barrier breakdown, extravasation of serum anti-IgG antibody, Purkinje cell targeting, gliosis, and acute neuronal necrosis in the cortex, subcortical and cerebellar Purkinje cells. Gluten peptides, probably causing extravasation of blood-born anti-gluten antibodies and selective targeting of Purkinje cells were observed in mice immunized with pt-gluding in CFA. Also, elevated levels of IFN-γ and IL-17 and upregulation of inflammatory chemokines CXCL-2, CCL-2, and CXCL-10, which played an essential role in leukocyte trafficking, could be considered as related immune-mediated responses against gluten.

CONFLICT OF INTEREST

The authors declare no conflicts of interest.

ACKNOWLEDGEMENTS

The authors are thankful to Dr. Ashkan Faridi, Dr. Mojtaba Abbasi, and Dr. Asadollah Mohammadi for their constructive comments and help prepare the manuscript and format it.

REFERENCES

1. Sander SD, Størdal K, Hansen TP, Andersen AdMN, Murray JA, Lillevang ST, et al. Validation of celiac disease diagnoses recorded in the Danish National Patient Register using duodenal biopsies, celiac disease-specific antibodies, and human leukocyte-antigen genotypes. Clin Epidemiol. 2016;8:789–99.
2. Caio G, Volta U, Sapone A, Leffler DA, De Giorgio R, Catassi C, et al. Celiac disease: a comprehensive current review. BMC Med. 2019;17:1d20.
3. Parzanese I, Qehajaj D, Patrinicola F, Aralica M, Chiriva-Internati M, Stifter S, et al. Celiac disease: From
4. Yu XB, Ubde M, Green PH, Alaedini A. Autoantibodies in the extraintestinal manifestations of celiac disease. Nutrients. 2018;10(8):1123.

5. Dupont FM, Vensel WH, Tanaka CK, Hurkman WJ, Altenbach SB. Deciphering the complexities of the wheat flour proteome using quantitative two-dimensional electrophoresis, three proteases and tandem mass spectrometry. Proteome Sci. 2011;11:9:10.

6. Shimada S, Tanigawa T, Watanabe T, Nakata A, Sugimura N, Itani S, et al. Involvement of gliadin, a component of wheat gluten, in increased intestinal permeability leading to non-steroidal anti-inflammatory drug-induced small-intestinal damage. PloS one. 2019;14(2):e0211436.

7. Abazari O, Shafaei Z, Divsalar A, Esiami-Moghadam M, Ghalandari B, Saboury AA. Probing the biological evaluations of a new designed Pt (II) complex using spectroscopic and theoretical approaches: Human hemoglobin as a target. J Biomol Struct Dyn. 2016;34(5):1123-31.

8. Ahmadabadi FB, Shahbazkhani B, Tafakhori A, Khosravi A, Mashhadi MM. A genetic study of celiac disease in patients with multiple sclerosis in comparison with celiac patients and healthy controls. Govaresh. 2018;22(4):256-60.

9. Thomsen HL, Jessen EB, Passali M, Frederiksen JL. The role of gluten in multiple sclerosis: A systematic review. Mult Scler Relat Disord. 2019;27:156-63.

10. Shiri-Shahsavar MR, Mirshafiee A, Parastouei K, Ebrahimi-Kalan A, Yekanineejad S, Soleymani F, et al. A Novel Combination of Docosahexaenoic Acid, All-Trans Retinoic Acid, and 1, 25-Dihydroxyvitamin D 3 Reduces T-Bet Gene Expression, Serum Interferon Gamma, and Clinical Scores but Promotes PPARγ Gene Expression in Experimental Autoimmune Encephalomyelitis. J Mol Neurosci. 2016;60(4):498-508.

11. Torkaman M, Ghollasi M, Mohammadnia-Arfaoui M, Salimi A, Amari A. The effect of transplanted human Wharton's jelly mesenchymal stem cells treated with IFN-γ on experimental autoimmune encephalomyelitis mice. Cell Immunol. 2017;311:1-12.

12. Singh I, Nath N, Saxena N, Singh AK, Won J-S. Regulation of IL-10 and IL-17 mediated experimental autoimmune encephalomyelitis by S-nitrosoglutathione. Immunobiology. 2018;223(10):549-54.

13. Abazari O, Divsalar A, Ghabadi R. Inhibitory effects of oxali-Platin as a chemotherapeutic drug on the function and structure of bovine liver catalase. J Biomol Struct Dyn. 2020;38(2):609-15.

14. Constantinescu CS, Farooqi N, O'Brien K, Gran B. Experimental autoimmune encephalomyelitis (EAE) as a model for multiple sclerosis (MS). Br J Pharmacol. 2011;164(4):1079-106.

15. Pinheiro MAL, Kooij G, Mizee MR, Kamermans A, Enzmann G, Lyck R, et al. Immune cell trafficking across the barriers of the central nervous system in multiple sclerosis and stroke. Biochim Biophys Acta Mol Basis Dis. 2016;1862(3):461-71.

16. Kuwabara T, Ishikawa F, Kondo M, Kakiuchi T. The Role of IL-17 and Related Cytokines in Inflammatory Autoimmune Diseases. Mediators Inflamm. 2017;2017:3908061.

17. Xu J, Neal LM, Ganguly A, Kolbe JL, Hargarten JC, Elsegeiny W, et al. Chemokine receptor CXCR3 is required for lethal brain pathology but not pathogen clearance during cryptococcal meningoencephalitis. Sci Adv. 2020;6(25):eaba2502.

18. Abazari O, Shafaei Z, Divsalar A, Esiami-Moghadam M, Ghalandari B, Saboury AA, et al. Interaction of the synthesized anticancer compound of the methyl-glucose 1, 10-phenanthroline platinum nitrate with human serum albumin and human hemoglobin proteins by spectroscopy methods and molecular docking. J Iran Chem Soc. 2020;1-14.

19. Kaushansky N, Bakos E, Becker-Herman S, Shachar I, Ben-Nun A. Circulating Picomolar Levels of CCL2 Downregulate Ongoing Chronic Experimental Autoimmune Encephalomyelitis by Induction of Regulatory Mechanisms. J Immunol Res. 2019;203(7):1857-66.

20. Hernandez-Lahoz C, Mauri-Capdevila G, Vega-Villar J, Rodrigo L. [Neurological disorders associated with gluten sensitivity]. Rev Neurol. 2011 1;53(5):287-300.

21. Lombardi E, Bergamo P, Maurano F, Bozzella G, Luongo D, Mazzarella G, et al. Selective inhibition of the gliadin-specific, cell-mediated immune response by transamidation with microbial transglutaminase. J Leukoc Biol. 2013;93(4):479-88.

22. Halon A, Donizy P, Biecek P, Rudno-Rudzinska J, Kielan W, Matkowski R. HER-2 expression in immunohistochemistry has no prognostic significance in gastric cancer patients. Sci World J. 2012;2012.

23. Wang D-W, Li D, Wang J, Zhao Y, Wang Z, Yue G, et al. Genome-wide analysis of complex wheat gliadins, the dominant carriers of celiac disease epitopes. Sci Rep. 2017;7:44609.
24. Escudie J-B, Rance B, Malamut G, Khater S, Burgun A, Cellier C, et al. A novel data-driven workflow combining literature and electronic health records to estimate comorbidities burden for a specific disease: a case study on autoimmune comorbidities in patients with celiac disease. BMC MED INFORM DECIS. 2017;17(1):140.

25. Shafaei Z, Abazari O, Divsalar A, Ghalandari B, Poursoleiman A, Saboury AA, et al. Effect of a Synthesized Amyl-Glycine1, 10dPhenanthroline Platinum Nitrate on Structure and Stability of Human Blood Carrier Protein, Albumin: Spectroscopic and Modeling Approaches. J Fluoresc. 2017;27(5):1829-38.

26. Martin ISM, Vilar EG, Yurrita LC. Can gluten contribute to degenerative and neuronal diseases? Still no evidence based results. JONNPR. 2016;1(1):3-12.

27. Palosuo K, Varjonen E, Nurkala J, Kalkkinen N, Harvima R, Reunala T, et al. Transglutaminase-mediated cross-linking of a peptic fraction of omega-5 gliadin enhances IgE reactivity in wheat-dependent, exercise-induced anaphylaxis. J Allergy Clin Immunol. 2003;111(6):1386-92.

28. Ozuna CV, Barro F. Characterization of gluten proteins and celiac disease-related immunogenic epitopes in the Triticaceae: cereal domestication and breeding contributed to decrease the content of gliadins and gluten. Mol Breed. 2018;38(3):22.

29. Petersen J, Ciacchi L, Tran MT, Loh KL, Kooy Winkelaar Y, Croft NP, et al. T cell receptor cross-reactivity between gliadin and bacterial peptides in celiac disease. Nat Struct Mol Biol. 2020;27(1):49-61.

30. Ouahidi I, Elhamsas AEY, Bouyahouzi Y, Mernissi FZ, Aarab L. Characterization and Stability of specific IgE to White Egg’s, Gliadin’s and Peanut’s Proteins among Children. Iran J Allergy Asthma Immunol.2010; 9(2): 97d102.

31. Musavi H, Abazari O, Barartabar Z, et al. The benefits of Vitamin D in the COVID-19 pandemic: biochemical and immunological mechanisms. Arch Physiol Biochem. 2020:1-9.

32. Kuang F, Wang BR, Zhang P, Fei LL, Jia Y, Duan XL, et al. Extravasation of blood-borne immunoglobulin G through blood-brain barrier during adrenaline-induced transient hypertension in the rat. INT J NEUROSCI. 2004;114(6):575-91.

33. Asadi A, Nezhad DY, Javazm AR, Khanicheragh P, Mashouri L, Shakeri F, et al. In vitro Effects of Curcumin on Transforming Growth Factor-β-mediated Non-Smad Signaling Pathway, Oxidative Stress, and Pro-inflammatory Cytokines Production with Human Vascular Smooth Muscle Cells. IJAAI. 2019:1-10.

34. Michalak Z, Lebrun A, Di Miceli M, Rouset MC, Crespel A, Couble P, et al. IgG leakage may contribute to neuronal dysfunction in drug-refractory epilepsies with blood-brain barrier disruption. J Neuropathol Exp Neurol. 2012;71(9):826-38.

35. Hadjivassiliou M, Zis P. Neurological manifestations of gluten sensitivity. Neurorheumatology. 2019:179-86.

36. Diaz-Castro J, Muriel-Neyra C, Martin-Masot R, Moreno-Fernandez J, Maldonado J, Nestares T. Oxidative stress, DNA stability and evoked inflammatory signaling in young celiac patients consuming a gluten-free diet. Eur J Nutr. 2019:1-8.

37. Zare Z, Dizaj TN, Lohrasbi A, et al. Silibinin inhibits TGF-β-induced MMP-2 and MMP-9 through Smad Signaling pathway in colorectal cancer HT-29 cells. Basic Clin Cancer Res. 2020;12(2):79-88.

38. Nanri K, Okuma M, Sato S, Yoneda M, Taguchi T, Mitoma H, et al. Prevalence of autoantibodies and the efficacy of immunotherapy for autoimmune cerebellar ataxia. Intern Med J. 2016;55(5):449-54.

39. Passali M, Josefsen K, Frederiksen JL, Antvorskov JC. Current Evidence on the Efficacy of Gluten-Free Diets in Multiple Sclerosis, Psoriasis, Type 1 Diabetes and Autoimmune Thyroid Diseases. Nutrients. 2020;12(8):2316.

40. Osipova ED, Semyachkina-Glushkovskaya OV, Morgun AV, Pisareva NV, Malinovskaya NA, Boissova EB, et al. Gliotransmitters and cytokines in the control of blood-brain barrier permeability. Rev Neurosci. 2018;29(5):567-91.

41. Camara-Lemarroy CR, Silva C, Greenfield J, Liu W-Q, Metz LM, Yong VW. Biomarkers of intestinal barrier function in multiple sclerosis are associated with disease activity. Mult. 2019:26(11),p:1340-1350.

42. Tanuma N, Sakuma H, Sasaki A, Matsumoto Y. Chemokine expression by astrocytes plays a role in microglia/macrophage activation and subsequent neurodegeneration in secondary progressive multiple sclerosis. ACTA NEUROPATHOL. 2006;112(2):195-204.